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Background: A National Institutes of Health-funded clinical trial of pa- 
tients undergoing coronary artery bypass randomized perfusate and myo- 
cardial preservation tocold, tepid, or warm temperatures. The goal of the 
trial was to evaluate neurologic function before and after operation (4 days 
and 1 month after operation) and to measure hematologic data for 
fibrinolytic potential. Methods: The three groups comprised 116 patients 
who completed neurologic evaluation by means of the Mathew scale out of 
130 entered into the trial (37 cold group, 50 tepid, and 43 warm). 
Twenty-five patients had complete hematologic studies done. All three 
groups were comparable before operation. The myocardial preservation 
protocol used blood cardioplegic solution at cold (8 ° to 10 ° C), tepid (32 ° C), 
or warm (37 ° C) temperature and the systemic perfusate temperature 
during cardiopnlmonary b pass was 20 ° (cold), 32°C (tepid), or 37°C 
(warm). Results: Patients in the cold group had a longer duration of 
intubation and postoperative hospitalization and a slightly but significantly 
higher peak postoperative creatine kinase MB level than patients in the 
warm group. There were no deaths. There was deterioration i  Mathew 
scale findings in all three groups, and no distinction could be made between 
groups. However, a significantly higher number in the cold group had an 
abnormal postoperative neurologic examination result that prompted 
computed tomographic scanning (18.9% cold, 2% tepid, 9.3% warm). A 
cerebrovascular accident was documented by computed tomographic s an- 
ning in 8.1%, 0%, and 4.7% of patients in the cold, tepid, and warm groups, 
respectively (not significant). Hematologic data documented significantly 
increased fibrinolytic potential in the warm group. Conclusions: Perfusion 
temperature is a factor in recovery from cardiopulmonary b pass. Cold has 
more adverse neurologic sequelae that prompt computed tomographic 
scanning whereas warm has more activation of fibrinolytic potential. Tepid 
is the best temperature for optimizing recovery from cardiopulmonary 
bypass. ( J  Thorac Cardiovasc Surg 1996;112:1622-33) 
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T he concept of warm heart operation was initiated at the University of Toronto in 1987.1 Before 
1987, cold preservation had been the gold standard 
and cold perfusion during cardiopulmonary b pass 
(CPB) was routinely used to avoid myocardial re- 
warming. With the introduction of warm myocardial 
preservation, the need for hypothermic perfusion 
was avoided and normothermic perfusion was pop- 
ularized. 2 There was concern, however, about the 
effects of normothermic perfusion on neurologic 
function and the possible deleterious effects of 
normothermic perfusion on the incidence of intra- 
operative stroke. 3 This research was designed to 
study this relationship in a controlled setting. 
An ongoing prospective, randomized National 
Institutes of Health-funded clinical trial was begun 
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in February 1994 to study the influence of CPB 
perfusate temperature during coronary revascular- 
ization on factors that affect recovery. Initial efforts 
were dedicated to the study of neurologic function 
on the basis of the Mathew scale, 4 as modified by 
Gelmers and associates, 5 done before operation, at 
postoperative day 3 or 4 (before discharge from the 
hospital), and at i month by a neurologist blinded to 
perfusion temperature. Additional parameters re- 
garding rapidity of recovery, such as time to extuba- 
tion, amount of postoperative blood loss, creatine 
kinase (CK) MB generation, perioperative myocar- 
dial infarction, and postoperative length of stay, 
were measured for each patient. Tests done only 
after initiation of the study, in recent months, have 
included measurements of fibrinolytic activity. 
Methods 
This study randomly selected one of three perfusion 
temperatures for CPB, cold (20 ° C), tepid (32 ° C), or 
warm (37 ° C). There were 130 patients randomized for 
this report who were divided into 37 patients in the cold 
group, 50 in the tepid, and 43 in the warm. The study was 
approved by the Baystate Medical Center Institutional 
Review Board and is scheduled for completion in 1997. 
Informed consent was obtained from every patient. Ran- 
domization was accomplished by a computer-generated 
random number assignment. All patients were random- 
ized in the operating room before the start of CPB into 
one of the three temperature protocols. 
Warm CPB was conducted with perfusate temperature 
strictly at 37 ° C, tepid at 32 °, and cold at 20 ° C. Only 
during rewarming from cold perfusion was deliberate 
hyperthermia (39 ° C) used for any part of the rewarming 
process, and this never, in any case, exceeded a 10°C 
temperature gradient. If the perfusate was cooled (to 
either 32 ° C or 20 ° C), then rewarming was initiated with 
the last distal anastomosis and was continued uring the 
placement of proximal aorta-saphenous vein anastomoses 
with use of a side-biting aortic clamp or single aortic 
crossclamp with continued arrest if aortic atheroma was 
noted. Rewarming was accomplished with a perfusion 
temperature up to 39 ° C in patients in the cold group and 
up to 37 ° C in patients in the tepid group. Patients were 
weaned from CPB after the rectal or nasopharyngeal core 
temperature reached 36 ° C. During cardioplegic arrest, 
core temperature ached 25 ° to 28 ° C, 32 ° to 33 ° C, and 
35 ° to 36 ° C in the cold, tepid, and warm groups, respec- 
tively. The surgeons participating in the study were the 
entire the Baystate Medical Center cardiac surgical staff 
(R. M. E.; J. A. R.; J. E. F.; D. W. D.). 
All patients having elective and urgent coronary revas- 
cularization with three or more bypass grafts (to ensure a 
bypass time in excess of 60 minutes) and younger than 76 
years old (to reduce the risk of aortic, carotid, or intra- 
cerebral atherosclerosis a a factor) were candidates for 
the study. Of the 130 patients, 40.8% required elective 
and 59.2% required urgent operation (defined as requir- 
ing operation as soon as feasible during the same hospi- 
talization). Exclusion factors were any neurologic disease 
history, poor ventricular function (left ventricular ejection 
fraction <30%), ongoing congestive heart failure, renal 
failure with serum creatinine level greater than 2.0 U/L, or 
recent postinfarction angina. Patients in whom the post- 
operative neurologic examination could not be done, for 
example, because of mortality, reoperation, poor ventric- 
ular function and low output syndrome, multisystem or- 
gan failure, or refusal to undergo afollow-up examination, 
were excluded from the current study and are included in 
a separate report. Data for patients in whom a tempera- 
ture protocol was not adhered to for any reason were 
reported with the patient's intent-to-treat group, for ex- 
ample, patients who required a cold perfusion tempera- 
ture for achieving cardioplegic arrest, and are described 
separately. 
Anesthesia was consistent across the three groups: 
premedication with lorazepam (1 to 2 mg orally); induc- 
tion with sufentanil (1 to 2 p~g/kg intravenously) or 
fentanyl (5 to 15 ixg/kg intravenously), midazolam (0.05 
mg/kg intravenously), and pancuronium (0.15 mg/kg in- 
travenously); and maintenance with sufentanil (<4 txg/kg 
intravenously) or fentanyl (<20 ~g/kg intravenously) and 
isoflurane titrated as tolerated (usually 0.5% to 1.0%). 
Extubation occurred in the intensive care unit as rapidly 
as feasible with use of standard respiratory parameters. 
All patients had a rectal temperature greater than 36 ° C 
before extubation. No attempt was made to deliberately 
maintain paralysis or analgesic medication to extend the 
duration of intubation, but if shivering occurred during 
recovery, medication was occasionally necessary until full 
rewarming. "Fast track" recovery was attempted in every 
patient o accomplish an expeditious discharge from the 
hospital. 6 Our fast track protocol used methylpred- 
nisolone 1 gm intravenously before bypass and dexameth- 
asone 4 mg intravenously every 6 hours for four doses (24 
hours) beginning immediately after operation. Steroid 
dose was reduced by 50% in patients with diabetes. 
The adequacy of myocardial preservation was gauged 
by (1) documentation of perioperative infarction with 
electrocardiographic or CK-MB criteria, or both; (2) 
recording of inotrope use, and (3) measurement of daily 
CK-MB levels. CPB used a Cobe roller pump (Cobe 
Cardiovascular, Inc., Arvada, Colo.) and the Affinity 
hollow fiber membrane (Avecor Cardiovascular, Inc., 
Plymouth, Minn.). An 8.0 mm Sarns aortic arch cannula 
(Sarns/3M Health Care, Ann Arbor, Mich.) or a 20F DLP 
arterial cannula (DLP, Inc., Grand Rapids, Mich.) was 
used for aortic cannulation, and a 36F dual-drainage 
Research Medical single venous return catheter (Re- 
search Medical, Inc., Midvale, Utah) was used for venous 
access. A DLP Gundry RCSP 15F coronary sinus catheter 
was used for retrograde delivery of cardioplegic solution. 
CBP was done at flow rates of 2 L/min per square meter 
or greater when the patients underwent hypothermia and 
up to 3 L/min per square meter during normothermia. 
In-line venous saturation was maintained at greater than 
70% and perfusion pressures deliberately maintained 
between 60 and 80 mm Hg with the use of phenylephrine 
for vasoconstriction a d isoflurane for vasodilation. The 
hematocrit value was maintained at 20% or greater during 
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Table I. Description of the Mathew scale 
Category Score 
Consciousness 8 
Orientation 6 
Language 23 
Strength 20 
Reflexes 3 
Sensation 3 
Visual fields 3 
Gaze palsy 3 
Facial weakness 3 
Disability 28 
Total 100 
the operation. Heparin was administered initially at 500 
u/kg body weight intravenously and CPB initiated only if 
the activated clotting time was greater than 600 seconds 
and the heparin level greater than 3 mg/kg body weight. 
Measurements of activated clotting time and heparin 
levels were repeated every 30 minutes during CPB, and 
heparin was administered as necessary. 
Myocardial preservation was by antegrade-retrograde 
blood cardioplegia with the use of 4:1 blood/crystalloid 
solution at the temperature chosen for the study. Cold 
preservation used 8 ° to 10 ° C blood cardioplegic solution, 
whereas tepid preservation used 32°C and warm 37°C 
solution. Cardioplegic solution was administered in a 
retrograde fashion and through each completed vein graft 
intermittently during the procedure in a similar manner 
regardless of temperature. Aortic venting was used in 
every patient. Whenever the retrograde flow of blood 
cardioplegic solution interfered with visualization of the 
anastomoses, infusion of the solution was interrupted. 
When we analyzed the percent of arrest time, when 
cardioplegic solution was actually administered in the 
majority of patients, the result was 70% of the total arrest 
time, and at no time was cardioplegia interrupted for 
more than 10 minutes at a time. 7 Hyperkalemia was 
avoided by using low-potassium cardioplegic solution 
(K + = 8 to 10 mEq/L) except for induction of arrest (K + 
= 24 mEq/L). Intraoperative hyperglycemia was avoided 
by sharply reducing crystalloid cardioplegic solution glu- 
cose administration such that the blood cardioplegic so- 
lution glucose levels were normoglycemic, with the blood/ 
crystalloid ratio at 4:1. 
The primary end point of the study was neurologic 
function. This was quantitatively assessed in every patient 
with use of the Mathew scale (Table I). This is an accepted 
measure that was scored before operation, 3 to 4 days 
after operation but before discharge from the hospital, 
and at 1 month when the patient returned for follow-up 
examination. When any abnormality was detected, a ce- 
rebral computed tomographic (CT) scan was done, and if 
a cerebrovascular ccident was diagnosed, a magnetic 
resonance imaging angiogram was completed. At opera- 
tion, to rule out aortic atherosclerosis, epiaortic echocar- 
diographic imaging was done in any patient for whom 
there was a suspicion of atheroma. If atherosclerosis was 
noted, the patient was included in the trial but specifics 
were noted as to the presence of aortic disease. 
Measurements of fibrinolytic potential were studied in 
collaboration with Colorado Coagulation Consultants, 
Inc. (Denver, Colo.). Six studies were done: tissue plas- 
minogen activator antigen (t-PA antigen), plasminogen 
activator inhibitor (PAI-1), plasma ntithrombin (PAT) 
(previously termed antithrombin III), plasminogen, pre- 
kallikrein, and c~2-antiplasmin. Each was done immedi- 
ately before operation, at the completion of operation (on 
admission to the intensive care unit), and at 2, 4, 12, and 
24 hours after operation. The tests required blood to be 
collected in 3.8% buffered citrate solution. Plasma was 
immediately separated and frozen at -70 ° C and shipped 
on dry ice to Colorado Coagulation Consultants for 
analysis. 
The specific techniques used for the hematologic stud- 
ies were (1) for t-PA antigen (measured in nanograms per 
milliliter), the BioPool TintElize test (BioPool/Meditec, 
Inc., Ventura, Calif.), which uses the double antibody 
principle and enzyme-linked immunosorbent assay meth- 
ods; (2) for PAI-1 (measured in units per milliliter), the 
BioPool Spectrolyse test (BioPool/Meditec), which is a 
two-stage, enzymatic assay; (3) for PAT (measured in 
percent activity), the Dade antithrombin III chromogenic 
assay, which measures the functional levels of PAT by an 
amidolytic method with use of a synthetic hromogenic 
substrate (Baxter Diagnostics, Inc., Deerfield, Ill.); (4) for 
plasminogen (measured in percent activity), the chromo- 
genic assay that measures the functional levels of plasmin- 
ogen by an amidolytic method with use of a synthetic 
chromogenic substrate (Pharmacia/Kabi, Franklin, Ohio); 
(5) for prekallikrein (measured in percent activity), the 
generally accepted one-stage activated partial thrombo- 
plastin time measurement (Colorado Coagulation Con- 
sultants); and (6) for c~2-antiplasmin (measured inpercent 
activity), the chromogenic assay that measures the func- 
tional levels in plasma by an amidolytic method with use 
of a synthetic substrate (Pharmacia/Kabi). Analyses were 
corrected in each instance for hemodilution by the follow- 
ing calculation: corrected concentration or activity = 
(sample concentration or activity)(initial hematocrit)/ 
(sample hematocrit). 
The data were analyzed in two ways: first, as the 
absolute change in activity, Xo - Xp, where Xc is the 
corrected postoperative value and Xp is the preoperative 
or baseline value, and second, as the relative change in 
activity, or percent change from baseline, 100(Xo - 
Xp)/Xp. In the first calculation, the measurement ex- 
pressed either a concentration or percent activity. In the 
second, the calculation expressed a percent change. If the 
level increased uring CPB, the value was positive and if 
it decreased, the value was negative. 
Statistical analysis and data collection. All patient 
data relative to recovery were collected prospectively by 
research assistants blinded to temperature. The data 
include the Society of Thoracic Surgeons database infor- 
mation, all atrial and ventricular arrhythmias (whether 
treated or not), time until extubation, blood collected 
after operation (whether einfused or not), blood and 
blood products transfused, and postoperative l ngth of 
stay. Temperature groups were compared with the use of 
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Table I I . Preoperative and intraoperative data on 130 National Institutes of Health patients 
Cold Tepid Warm 
Preoperative data 
No. of patients 37 50 43 
Mean age (yr) 65.9 +_ 1.3 62.9 _+ 1.1 60.5 -+ 1.3 
Range of age (yr) 47-75 41-75 45-74 
Men (%) 67.6 84.0 81.4 
Diabetes (%) 21.6 36.0 23.3 
Hypertension (%) 54.1 64.0 65.1 
COPD (%) 8.1 8.0 0.0 
History of myocardial infarction (%) 45.9 52.0 37.2 
History of unstable angina (%) 59.5 56.0 51.2 
Left main disease (%) 29.7 24.0 20.9 
Mean ejection fraction (%) 51.6 _+ 1.5 51.9 _+ 1.3 52.1 +_ 1.5 
Operative data 
No. of grafts (mean) 3.8 _+ 0.1 4.0 _+ 0.1 3.9 _+ 0.1 
Internal thoracic artery used (%) 100 100 95.3 
Mean CPB time (min) 140.4 _+ 5.7 141.7 _+ 5.5 137.5 _+ 5.7 
Mean crossclamp time (min) 84.0 _+ 3.8 88.2 _+ 4.2 86.5 _+ 4.2 
Crystalloid cardioplegic solution (ml)* 1672 _+ 92.2? 2113 _+ 120.2? 1945 _+ 118.1 
*Amount of crystalloid cardioplegic solution: total cardioplegic volume is divided by 5 because blood is 4:1 crystalloid. 
1",o < 0.01 by t test. 
simple descriptive statistics such as the mean plus or 
minus standard error and selected percentiles for some 
variables. Significance, defined at the a = 0.05 level, was 
determined by )(2 or Fisher's exact tests for association, 
Mantel-Haenszel X 2 tests for ordered trend across tem- 
perature groups for categorical variables, and by least 
squares or Kruskal-Wallis analysis of variance for contin- 
uous scale data. Nonparametric methods were used when 
the distributional ssumptions were in doubt, particularly 
with the presence of extreme values, which skew the 
distribution and can result in large differences in error 
variances across groups. Values reported in the tables are 
means plus or minus standard errors, even when a non- 
parametric test was used to assess ignificance. When differ- 
ences among the three groups were noted, pairwise ttests (or 
a t test approximation to Wilcoxon rank-sum statistic), with 
use of a Bonferroni correction for multiple comparisons, 
were used to determine where the differences lay. 
A multivariate analysis of variance was used to evaluate 
differences across the temperature groups in change from 
preoperative values (absolute and percent change) for the 
six hematologic factors. Significance tests for differences 
among the temperature groups, as well as ordered trend 
across temperature, were conducted for each factor and 
across all factors. 
Results 
Preoperative and operative variables (Table II) 
were comparable among groups and only volume of 
cardioplegic solution differed significantly across 
temperature groups. Mean age was 61 to 66 years 
and ejection fraction was 52%. All patients, except 
two, received internal thoracic artery grafts with the 
mean number of grafts near 4.0. Mean crossclamp 
time was 84 to 88 minutes in all three groups, and 
mean CPB time was 138 to 142 minutes, a reflection 
of how uniform the operative approach was regard- 
less of temperature. As expected, the smallest vol- 
ume of cardioplegic solution was administered in 
the cold group (p < 0.01 cold versus tepid; not 
significant cold versus warm). 
Postoperative data (Table I I I )  document differ- 
ences, which do not, however, always reach signifi- 
cance. The highest mean weight gain, longest mean 
duration of  intubation, and longest mean postoper- 
ative length of stay all occurred in the cold group, 
which is perhaps a reflection of longer intensive care 
unit stays necessitated by hypothermia. The analysis 
of variance on ranked values (Kruskal-Wallis) 
showed length of stay approaching significance 
across temperature (p = 0.09), and by pairwise 
comparison (Wilcoxon statistic) length of stay in the 
cold group was significantly longer than that in the 
tepid group (p = 0.02). Mean blood loss was least in 
the cold group but the difference did not reach 
significance. No patient in the cold group required 
reoperation because of bleeding whereas one pa- 
tient in the tepid group and two in the warm group 
had to have a reoperation. Blood or blood product 
administration at any time during postoperative 
hospitalization took place in only 26% to 32% of 
patients, with no distinction as to group. There was 
no perioperative or late mortality in any group. The 
prevalence of atrial fibrillation, including transient, 
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Table III. Postoperative data on 130 National Institutes of Health patients 
Cold Tepid Warm 
No. of patients 37 
Perioperative mortality (%) 0 
Peak postoperative weight gain (kg) 4.9 _+ 2.7 
Mean intubation time (hr) 11.6 _+ 1.7 
Peak postoperative CK-MB level (u/L) 43.4 _+ 4.2* 
Inotrope use (%) 32.4 
Intraaortic balloon pump (%) 2.7 
Postoperative length of stay (days) 7.0 -+ 0.8* 
Discharge within 3-5 days (%) 56.8 
Range of length of stay (days) 3-21 
New focal deficit on postoperative n urologic 18.9" 
examination (%) 
CT scan-confirmed stroke (%) 8.1 
Blood loss (ml) 831.2 _+ 56.8 
Patients not receiving blood products postoperatively (%) 67.6 
50 43 
0 0 
1.2 -+ 1.0 1.8 -+ 0.6 
10.4 -+ 0.9 10.1 -+ 0.9 
39.4 -+ 3.2t 33.5 -+ 2.6* 
34.0 23.3 
2.0 7.0 
5.2 -+ 0.2* 5.6 -+ 0.4 
72.0 65.1 
3-9 3-16 
2.0* 9.3 
0.0 4.7 
963.8 -+ 82.9 912.5 + 98.9 
74.0 67.4 
*p < 0.05 by Fisher's exact test or t test. 
tThe only patient with a perioperative infarction is omitted from this table but not from the statistical nalysis of the data. 
was 20% to 28% in the three groups, and atrial 
fibrillation that necessitated any specific therapy 
other than digoxin, which was used routinely, was 
18.9%, 14.0%, and 9.3% in the cold, tepid, and 
warm groups, respectively (not significant). Ventric- 
ular tachycardia (defined as 3 or more ventricular 
premature complexes together) occurred in 16% to 
28% of patients with no significant difference among 
groups. 
Myocardial injury as reflected by perioperative in- 
farction occurred in only one patient in the tepid 
group. Mean CK-MB generation was least in the warm 
group (33.5 u/L warm versus 43.4 u/L cold, p < 0.05). 
Inotrope use, a reflection of myocardial function, was 
also least in the warm group (23% warm, 34% tepid, 
32% cold), but this difference was not significant. 
Remarkably, the use of an intraaortic balloon at any 
time was highest in the warm group (three patients), 
with one each in the cold and tepid groups. Any 
profound influence of temperature on myocardial 
preservation was not clearly apparent in this study. 
Neurologic function. One hundred sixteen of the 
130 patients completed all three neurologic exami- 
nations (Table IV). Fourteen patients did not com- 
plete one of the postoperative neurologic examina- 
tions. Two underwent reoperation because of 
bleeding, two had low-output syndrome, and two 
had prolonged intubations that prevented full neu- 
rologic examinations a  scheduled. Eight additional 
patients missed a follow-up examination. None of 
these 14 patients had an adverse neurologic out- 
come, but they were excluded from the Mathew 
scale analysis. The distribution of these patients 
across groups was three in the cold, five in the tepid, 
and six in the warm group. One patient was random- 
ized to the cold group but received the warm 
method because of physician preference. There was 
no Mathew scale deterioration i  this patient. No 
other patient changed temperature groups. 
There was a uniform decrease in Mathew scale 
findings from preoperative to postoperative scores 
across all groups (p = 0.0001) and from preopera- 
tive to 1-month follow-up (p = 0.0001) (Table V). 
The distinction among groups was not significant 
(p > 0.5). There was significant improvement in 
scores between early postoperative and 1-month 
follow-up examinations (p = 0.0001), which again 
was not different among groups. The percent of 
patients with no deterioration in Mathew scale 
scores at any time after operation was 31.4%, 
28.9%, and 30.6% in the cold, tepid, and warm 
groups, respectively. This difference was not signif- 
icant. 
The Mathew scale (Table I) provides a means 
suggesting the diagnosis of stroke associated with 
coronary revascularization bygrading the severity 
of neurologic dysfunction and quantitating later- 
alizing signs of motor, visual, and reflex function. 
When there was any evidence of localizing neuro- 
logic dysfunction consistent with cerebrovascular 
accident, no matter how mild, a CT scan was 
obtained. Twelve patients, seven in the cold group 
(18.9%), one in the tepid (2.0%), and four in the 
warm (9.3%), were referred for diagnostic CT 
scanning (Table III). The association of bypass 
temperature with abnormal neurologic examina- 
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Table IV. Mathew scale summary 
N Mean +_ SEM 
Preop-test 
Cold 35 99.0 -+ 0.23 
Tepid 45 99.4 _+ 0.17 
Warm 36 99.0 -+ 0.52 
All 116 99.1 +_ 0.19 
Postop. test 
Cold 35 94.6 ± 0.93 
Tepid 45 96.2 + 0.67 
Warm 36 95.1 _+ 1.12 
All 116 95.4 ± 0.52 
Follow-up test 
Cold 35 97.7 ± 0.61 
Tepid 45 97.6 + 0.54 
Warm 36 98.1 ± 0.66 
All 116 97.7 -+ 0.34 
At no time was there a significant difference between temperature groups. 
SEM,, standard error of the mean. 
tion results prompting CT scanning was significant 
across the different emperatures (p = 0.02 by 
Fisher's exact test). CT scanning confirmed a 
cerebrovascular accident in only three patients in 
the cold group (8.1%), none in the tepid group 
(0%), and two in the warm group (4.7%). This 
difference was not significant (p = 0.10 by Fisher's 
exact test). Magnetic resonance angiography was 
done in all five patients with positive findings on 
CT scan and documented no intracerebral or 
extracerebral therosclerosis a a cause for cere- 
brovascular accident. This supports embolization 
as the most likely cause. For purposes of com- 
paring this study with less critical reports of 
postoperative n urologic dysfunction, of this five- 
patient cerebrovascular ccident group, only two 
had a grossly apparent stroke that would have 
been noted by routine examination (as distin- 
guished from a sophisticated preoperative and 
postoperative n urologic examination) and all five 
had complete recovery on long-term (3 month) 
follow-up. In three patients with cerebrovascular 
accident, neither the patients nor their families 
were aware of any neurologic dysfunction. 
An atherosclerotic ascending aorta was noted 
before bypass by epiaortic imaging in two patients, 
both in the warm group. Measures were taken, such 
as femoral arterial cannulation and single aortic 
clamping, to prevent embolization, but despite this, 
one of the two patients had a cerebrovascular acci- 
dent, which was small and from which recovery was 
complete. This same patient is included as one of 
the five in the overall series. 
Table V. Mathew scale difference 
N Mean ± SEM 
Postop.-preop. difference 
Cold 35 -4.3 _+ 0.98* 
Tepid 45 -3.3 + 0.67* 
Warm 36 -3.9 -+ 1.08" 
All I16 -3.7 ± 0.51" 
Follow-up-preop. difference 
Cold 35 -1.3 _+ 0.64* 
Tepid 45 -1.8 _+ 0.51" 
Warm 36 0.9 -+ 0.33* 
All 116 -1.4 ± 0.29* 
Follow-up-postop. difference 
Cold 35 +3.0 _+ 0.98* 
Tepid 45 + 1.4 _+ 0.70* 
Warm 36 +2.9 _+ 1.17" 
All 116 +2.4 + 0.54* 
Minus sign indicates adecrease andplus ign an increase in Mathew scale 
score. SEM, standard error of the mean. 
*A significant difference withp = 0.0001 for postoperative to preoperative 
comparison, follow-up to preoperative comparison, and follow-up to 
postoperative comparison, with no difference between groups. 
Fibrinolytic potential. The volume of postopera- 
tive blood loss was not significantly different across 
the three temperature groups (Table III) (mean = 
831 ml cold, 964 ml tepid, 913 ml warm) although it
was clearly least in the cold group. Additionally, no 
patient in the cold group required reoperation be- 
cause of bleeding. If the three patients (one in the 
tepid and two in the warm group) with reoperations 
are deleted from the blood loss analysis, the volume 
of blood collected after operation was similar among 
groups (831 _+ 57 ml cold, 906 _+ 61 ml tepid, 796 _+ 
58 ml warm). No antifibrinolytics were used in the 
study (for example, e-aminocaproic a id, tranexamic 
acid, or aprotinin). Although ematologic data were 
collected before CPB and after CPB at 0, 2, 4, 12, 
and 24 hours after operation, the only data to be 
discussed in depth will be measurements taken 
immediately after CPB. In this analysis of CPB 
temperature, fibrinolytic assay differences were most 
evident at completion of CPB. 
Six different hematologic features were measured, 
each having a role in CPB-induced fibrinolysis or 
fibrinolytic potential. A comparison was done for 
each measurement i  the preoperative determina- 
tion for differences across temperature groups and, 
as expected, there was no significant difference 
found. Each postoperative alue was corrected for 
hemodilution and the actual differences between the 
postoperative and preoperative l vels are presented 
in Table VI. The determination f a percent change 
from preoperative alues is described in Table VII. 
1 6 2 8 Engelman et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1996 
Table VI. Hematologic summary data for difference between postoperative and preoperative values 
Test Temperature N Mean +_ SEM ANOVA Trend 
t-PA antigen (ng/ml) 
PAI-1 (u/ml) 
PAT (% activity) 
Plasminogen (% activity) 
Prekallikrein (% activity) 
a2-Antiplasmin (% activity) 
Cold 9 +18.56 -+ 3.29* 
Tepid 6 +11.32 _+ 3.12" 
Warm 10 +15.96 _+ 3.22* 0.372 0.560 
All 25 +15.78 -- 1.91' 
Cold 9 +24.09 _+ 5.75* 
Tepid 6 +16.07 _+ 7.21 
Warm 10 +27.78 + 5.71" 0.451 0.654 
All 25 +23.64 _+ 3.51" 
Cold 9 -1.93 + 3.40 
Tepid 6 +6.38 _+ 8.90 
Warm 10 11.55 _+ 4.85* 0.098 0.192 
All 25 -3.78 _+ 3.31 
Cold 9 +3.04 _+ 5.42 
Tepid 6 -6.71 _+ 5.52 
Warm 10 -19.61 +_ 5.33* 0.018 0.0053 
All 25 -8.36 -- 3.66* 
Cold 9 -2.47 _+ 6.23 
Tepid 6 -8.36 _+ 7.29 
Warm 10 -27.56 _+ 6.39* 0.025 0.0092 
All 25 -13.92 _+ 4.34* 
Cold 9 +5.11 _+ 3.80 
Tepid 6 -1 .14 _+ 7.03 
Warm 10 -12.75 + 8.31 0.165 0.064 
All 25 -3.54 + 4.14 
SEM, Standard error of the mean; ANOVA, analysis of variance. 
*Significant change from preoperative alue, p < 0.05. 
The differences across temperature groups were 
tested for significance by analysis of variance. In 
addition, a test for linear trend across the three 
temperature groups ordered as cold-tepid-warm was 
evaluated. These results are reported in Tables VI 
and VII. 
Among the studies done, a significant empera- 
ture-dependent difference was noted only in the 
decrease in plasminogen and prekallikrein levels 
with the greatest decrease occurring in patients in 
the warm group and the least in patients in the cold 
group. The analysis of variancep value was 0.018 for 
plasminogen and 0.025 for prekaUikrein with a trend 
analysis p value of 0.0053 for plasminogen and 
0.0092 for prekallikrein. The percent change from 
the preoperative alue between groups was also only 
significantly different across the three groups in 
plasminogen and prekallikrein levels with similar p 
values for both analysis of variance and the linear 
trend. The fact that both analyses were statistically 
consistent underscores the validity of the data. 
A multivariate analysis across the six factors mea- 
sured for an overall temperature ffect was not 
significant (F approximations to Hotelling-Lawley 
trace, Roy's largest root). Although the warm group 
in general had the greatest negative score, this was 
not consistent across all factors and the ordering of 
cold and tepid was also not consistent (p = 0.258 for 
linear trend effect). 
As described in Tables VI and VII, neither all 
groups nor all studies had postoperative findings 
that were signifcantly different from preoperative 
control findings. The endothelial-generated fibrino- 
lytic t-PA antigen and antifibrinolytic PAI-1 showed 
uniform changes across all temperature groups with 
a significant increase in postoperative t.-PA antigen 
and PAI-1 levels. With regard to PAT, plasminogen, 
and prekallikrein only the warm group had a signif- 
icant decrease from preoperative values, whereas 
the other two groups either showed a small insignif- 
icant increase or values that remained near the 
preoperative l vel. 
Discussion 
The impetus of this study was to determine 
whether perfusion temperature could be a factor in 
recovery from CPB. Clearly, in only a minority of 
operations i there an overriding reason for choos- 
ing one temperature over any other, as for example 
in hypothermic circulatory arrest. When myocardial 
hypothermia was routinely favored for preservation, 
systemic hypothermia seemed appropriate. Now 
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Table VII. Hematologic summary data for percent difference from preoperative values 
Test Temperature N Mean +_ SEM ANOVA Trend 
t-PA antigen (ng/ml) 
PAI-1 (u/ml) 
PAT (% activity) 
Plasminogen (% activity) 
Prekallikrein (% activity) 
c~2-Antiplasmin (% activity) 
Cold 9 
Tepid 6 
Warm 10 
All 25 
Cold 9 
Tepid 6 
Warm 10 
All 25 
Cold 9 
Tepid 6 
Warm 10 
All 25 
Cold 9 
Tepid 6 
Warm 10 
All 25 
Cold 9 
Tepid 6 
Warm 10 
All 25 
Cold 9 
Tepid 6 
Warm 10 
All 25 
+146.9 ± 25.7* 
+119.7 ± 41.3" 
+180.0 -+ 51.4" 0.633 0.566 
+153.6 ± 24.2* 
Normal PAI-1 is 0-15 u/ml. To avoid an unrealistic percent calculation 
based on an increase from 0, these data are reported only as the actual 
difference from preoperative values in Table VI. 
-1 .7  -+ 3.8 
+6.5 -+ 9.6 
-12.2 -+ 5.4 0.120 0.199 
3.9 ± 3.6 
+6.1 ± 6.2 
--5.0 -+ 6.2 
-18.1 +- 5.0* 0.016 0.0046 
-6 .2  ± 3.9 
-1 .4 -+ 5.7 
-6 .6  ± 7.0 
-24.1 -+ 5.4* 0.023 0.0085 
-11.7 -+ 3.9* 
+5.0 ± 3.3 
-0 .9 -+ 7.1 
-11.0 -+ 7.4 0.180 0.070 
-2.8 ± 3.8 
SEM, Standard error of the mean; ANOVA, analysis of variance. 
*Significant change from preoperative value, p < 0.05. 
that myocardial hypothermia is no longer an issue, 
systemic perfusion temperature becomes a point of 
obvious discussion. As evident in this study, myocar- 
dial and cardioplegic solution temperatures had no 
dramatic effect on either myocardial preservation or 
the prevalence of arrhythmias (atrial or ventricular) 
and do not deserve to dictate a specific perfusion 
temperature. The CK-MB levels, although higher in 
cold-group than warm-group patients, were low and 
not consistent with myocardial infarction. CK-MB 
levels in the tepid group were between those in the 
cold and warm groups. 
In this era of shrinking health care funding, the 
rapidity of postoperative recovery from anesthesia 
and extubation and appropriate shortening of inten- 
sive care unit stays have become subjects of more 
than passing interest. As shown by our own group 6 
and by Westaby and associates, 8 early extubation is 
cost-effective and expedites recovery. Maintaining 
intensive care only for a short interval is clearly 
important for a host of reasons and can be more 
easily accomplished if significant hypothermia is 
avoided. As shown in this study, although the differ- 
ence was not statistically significant, reduced intu- 
bation time was temperature dependent and a sig- 
nificantly longer postoperative length of stay was 
associated with hypothermic perfusion. 
Neurologie function. Patients in all three temper- 
ature groups had lower Mathew scale scores at the 
immediate postoperative valuation. There was no 
difference among groups and there was significant 
improvement at 1-month follow-up, again with no 
apparent difference among groups (Table V). The 
percentage of patients with any decrease in score at 
any time after operation was 68.6%, 71.1%, and 
69.4% in the cold, tepid, and warm groups, respec- 
tively, which was not significantly different among 
groups. This is consistent with the findings of other 
investigators who have reported postoperative neu- 
ropsychologic impairment in as many as 79% of 
patients, 9the cause of which is clearly multifactorial. 
Insofar as microemboli during CPB have been im- 
plicated, there would be, on the surface at least, 
reason to suspect hypothermic CPB to be neuropro- 
tective.3, 10, 12 This was not the case, however, in 
other studies 1°' 12 or in the present one, which have 
clearly shown no improved neurologic outcome with 
hypothermic perfusion. 
The consequence of cold perfusion, in fact, is to 
lead to a significantly higher prevalence of abnormal 
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neurologic examinations prompting CT scanning 
(18.9% cold group versus 2.0% tepid and 9.3% 
warm, p -- 0.02). Although not associated with CT 
scan abnormalities in most patients, there remained 
a higher cerebrovascular accident prevalence in the 
cold group than in the tepid or warm groups (8.7% 
cold, 0% tepid, 4.7% warm: difference not signifi- 
cant, p = 0.10). The explanation for this seeming 
contradiction with the cold group having worse 
central nervous system function is speculative at 
best. A randomized, prospective trial was conducted 
through the University of Toronto and reported by 
Wong and associates I° in 1992. The investigators 
with a total of 34 patients found no new focal deficits 
in any of the groups but neuropsychologic test 
results were better in the warm group with one of 
seven tests reaching significance for warm versus 
cold (trail-making test A, p = 0.023). There was no 
explanation offered for why function should have 
been better in the warm group. Singh, Bert, and 
Feng 12 performed a retrospective analysis in which 
findings in a large number of patients in a warm 
group (2383) were compared with findings in a 
preceding cold group (1605), and they found a lower 
rate (difference not significant) of neurologic om- 
plications in the warm group. Again, no explanation 
was given for this finding. Finally, Martin and asso- 
ciates 3reported on a randomized, prospective trial 
done at Emory University that documented a signif- 
icantly higher prevalence of neurologic injury in the 
warm group. This was attributed to transient cere- 
bral hypoperfusion, hyperglycemia, and microembo- 
lization during CPB, which is more damaging in the 
normothermic setting. 
It is the latter study that perhaps provides the 
most insight into this problem. The Emory group 
presented this paper at the Society of Thoracic 
Surgeons' annual meeting in 1993. 3The oral presen- 
tation described in detail the actual mechanics of 
CPB, specifically the perfusate temperature, which 
was not elaborated on in the published paper. The 
patients treated with a warm method were main- 
tained deliberately at a core temperature near 37 ° C 
and perfusion was therefore hyperthermic (usually 
39°C and never higher than 40 ° C). 13 It is the 
contention of our investigative group that hyper- 
thermia is deleterious and contributes to central 
nervous system dysfunction. Prolonged hyperther- 
mia, as during an entire CPB period, is simply 
prolonging the risk of central nervous ystem injury. 
Cold perfusion similarly is usually associated with 
rewarming hyperthermia and may thereby also lead 
to central nervous system dysfunction. 14'1s This 
proposition is difficult, if not impossible, to prove 
but is supported by others, 15 with a finding by the 
Mayo Clinic group of cerebral venous desaturation 
in 50% of patients during hyperthermic rewarming 
after standard hypothermic CPB. 14 
The results of neuropsychologic tests, such as 
those from the trail-making test, which Wong and 
associates 1° found more depressed in cold-group 
patients, may indicate slower recovery from hypo- 
thermic rather than normothermic CPB without 
apparent central nervous system pathologic occur- 
rences. Indeed, Townes and associates 16found neu- 
robehavioral outcomes depressed inpatients treated 
with hypothermia with resolution over time in the 
majority. The rapidity and normality of mentation 
can clearly be depressed by CPB, particularly when 
hypothermia is used, without apparent anatomic 
changes and ultimately complete recovery. 
Fibrinolytic potential. The schematic for CPB- 
induced fibrinolysis is depicted in Fig. 1. Blood 
during CPB is in contact with foreign surfaces, which 
leads to activation of factor XII. 17 Activated factor 
XII converts plasminogen to plasmin. This is accel- 
erated by the contact conversion of prekallikrein to 
kallikrein, a consequence of heparin and CPB. 17-19 
Endothelial cell perturbations also occur during 
CPB, ischemic stress, and cardioplegia nd contrib- 
ute to generation of both a fibrinolytic or antithrom- 
boric response, t-PA, and an antifibrinolytic or pro- 
thrombic response, PAI-1. 2°-22 These function in a 
fibrinolytic pathway to both stimulate and inhibit 
fibrinolysis. When both t-PA and PAI-1 are gener- 
ated, the former is more physiologically dominant. 23 
Valen and associates 22measured t-PA and PAI-1 
levels both during and after CPB. Although they 
found t-PA antigen levels to increase both during 
and after CPB, PAI-1 activity only increased after 
CPB. In the present study, measurements were 
made only after CPB and the results were similar to 
those reported by Valen and associates. 22There is a 
clear increase in fibrinolytic potential as seen with 
t-PA generation during CPB, which is the more 
dominant enzyme and is offset in part by PAI-1 
release after operation. 22' 23 The changes in these 
agonist/antagonists were not temperature depen- 
dent but occurred uniformly across all temperatures. 
This implies comparable ndothelial stimulation at 
all three temperatures. 
Plasminogen is degraded to plasmin in the pro- 
cess of promoting fibrinolysis. In this study, plasmin- 
ogen levels decreased significantly as a percent of 
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Fig. 1. Schematic for fibrinolytic potential occurring during CPB is illustrated. Blood and artificial surface 
contact lead to activation of Hageman factor (factor XII) and conversion of prekallikrein to kallikrein. 
Both serve to degrade plasminogen i to plasmin. Activated factor XII, through its initiation of clotting 
cascade promotes formation of thrombin from prothrombin. Disturbances affecting endothelial cell, such 
as myocardial ischemia and cardioplegia, promote formation of t-PA, which functions to support 
degradation fplasminogen toplasmin. An antifibrinolytic, PAI-1, is also formed from endothelium, and 
functions to interrupt degradation fplasminogen. Plasmin, in turn, acts on fibrinogen and fibrin to form 
degradation products, which are end stage of fibrinolysis. Interfering with activity of plasmin is 
a2-antiplasmin (a-2-ANTIPL). PAT interrupts activity of thrombin in forming fbrin from fibrinogen. 
Specifically measured in this analysis were studies marked with asterisk: t-PA antigen, PAI-1, PAT, 
plasminogen, prekallikrein and %-antiplasmin. 
preoperative control values only in the warm group 
( -18% +_ 5%; p = 0.005). The changes in the tepid 
( -5% +_ 6%) and cold (+6% _ 6%) groups were 
not significant. This finding documents a significant 
difference in fibrinolysis with only warm perfusion 
promoting a significant degradation ofplasminogen. 
The results with prekallikrein are similar with no 
significant difference noted in the cold or tepid 
groups but a significant decrease ( -24% +_ 5%) in 
the warm group (p = 0.002). This finding, together 
with a significant ordering across temperature 
groups for both quantitative measures of fibrinolysis 
(plasminogen and prekallikrein), supports the con- 
clusion that artificial surface-induced fibrinolysis is 
temperature dependent. This study has shown nor- 
mothermic perfusion to lead to increased fibrino- 
lytic potential. The tests that documented this were 
increased t-PA antigen, decreased PAT, lowest plas- 
minogen, lowest prekallikrein, and lowest a2-anti- 
plasmin in normothermic patients. Neither tepid nor 
cold treatment had the same results. Whether this is 
only a result of increased surface activation of 
fibrinolysis or of a combination of factors in the 
normothermic group including increased endothe- 
lial stimulation cannot be definitively stated. How- 
ever, this study does not have any data to support an 
increased endothelial component to normothermic 
bypass. Of interest in this regard is the finding of 
reoperation because of bleeding being necessary in 
two warm-group, one tepid-group, and no cold- 
group patients. 
Conclusion. There is a detriment o both cold 
and warm perfusion that is manifested by an in- 
crease in neurologic dysfunction i  patients receiv- 
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ing cold perfusion and an increase in fibrinolytic 
potential in patients receiving warm perfusion. Myo- 
cardial preservation temperature should not dictate 
perfusion temperature. The common practice of 
allowing the perfusate temperature to drift toward 
room temperature is most consistent with tepid 
perfusion. Rewarming during the latter phase of 
perfusion should not be hyperthermic or at least 
should be limited to a temperature close to 37 ° C. If 
hyperthermia s necessary for rewarming, it should 
be for as short an interval as possible, with recogni- 
t ion of the inherent dangers. 
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Discussion 
Dr. Robert A. Guyton (Atlanta, Ga.). We performed a
prospective, randomized trial of warm heart operation 
versus moderate hypothermia, which was published in 
1994. Our warm group had a target bladder temperature 
of 37 ° C, and hyperthermic arterial perfusion pressures 
with a maximum temperature of 38.5 ° C were necessarily 
used. Our conclusion was similar to the current conclu- 
sion. Hyperthermic arterial perfusion and consequent 
possible cerebral hyperthermia may be an important 
operative factor in the cause of neurologic injury. There 
are now nice studies in the neuroscience literature that 
examine the release of excitatory neurotransmitters and 
neurologic injury in response to temporary ischemia. 
Considerable neuroprotection is conferred with only 2 ° or 
3 ° of hypothermia; that is, 33°C is better than 37 ° C. 
These same studies have shown a dramatic negative ffect 
of hyperthermia. On the basis of our studies, the Toronto 
work, the current study, and the neuroscience studies, we 
believe that tepid temperatures are neuroprotective, nor- 
mothermia is not neuroprotective, and hyperthermic per- 
fusate temperatures increase neurologic damage. 
I have two questions for the authors regarding this 
superb study. First, I understand the difference that is 
suggested between the tepid and warm groups with regard 
to clinical neurologic deficits. I am uncomfortable, how- 
ever, with the implication that hyperthermic perfusion 
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fully explains the deficit rate in the cold group. The brain 
is hyperthermic only for a short time. In our own study we 
used hyperthermic warming perfusate in the cold group 
without observing a high neurologic deficit rate. Is there 
another eason for the deficits? For example, in the cold 
group, the average age was 66 years and in the warm 
group the average age was only 61, which is not a 
significant difference, but perhaps was a contributing 
difference. 
Finally, our study was terminated by our safety commit- 
tee when we demonstrated a neurologic deficit rate with a 
p value of 0.02. Because the authors have demonstrated 
an increased neurologic deficit rate or neurologic abnor- 
mality rate in the cold group with ap value of 0.01, do they 
plan to continue the study with inclusion of the cold group 
or do they plan to eliminate the cold group as they 
continue the study? 
Dr. Engelman. With regard to the question raised by 
concerns about cold perfusion, we now are aware of the 
risks of hyperthermic perfusion and are clearly limiting 
our hyperthermic perfusion to a much shorter interval 
during the bypass run with instructions given to our 
perfusionists as to what is necessary. 
With regard to the concerns raised about neurodysfunc- 
tion, we raised this issue with our institutional review 
board, and the decision made was based on the absolute 
finding of cerebrovascular accident, not just subtle neuro- 
logic dysfunction, which clearly is transient and may be 
more a subjective finding on the part of the neurologist 
rather than the objective finding that we have when we 
find a cerebrovascular ccident. With the CT scan as the 
gold standard for determination of nenrologic abnormal- 
ity, we believe that there was no significant difference 
between the various groups, and therefore the institu- 
tional review board has thought that it would not be 
necessary at this time to terminate the study. 
Dr. Thomas A. Orszulak (Rochester, Minn.). One of my 
colleagues, Dr. David Cook, a cardiac anesthesiologist at 
our institution, has performed both laboratory and pro- 
spective clinical research in which I have participated. We 
have embraced normothermic bypass for many of our 
clinical procedures and research projects and have also 
found that there was no statistical difference between 
hypothermic and normothermic perfusion when analyzing 
for neurologic function; however, our exclusions included 
patients with carotid bruits and diabetes, which I believe 
the authors' group included. 
The authors have presented timely information on a hot 
topic, which may offer a possible strategic ompromise or 
a shift in the practice between hypothermia nd normo- 
thermia with a tepid alternative. This may be a legitimate 
recommendation for the broad-based clinical cardiac sur- 
gical practice; however, I am not sure the data presented 
here provide irrefutable support for the tepid perfusion 
temperature. 
I have several questions. In the manuscript the authors 
state that the patients were computer andomized; how- 
ever, the groups were quite unequal at 37, 43, and 50 and 
they may be too small for heavy statistical weighting. 
Please explain this distribution and comment on the 
possibility that larger cohorts of patients may demonstrate 
a statistical difference. 
Second, neurologic findings that prompted a CT scan 
were statistically different between the cold and tepid 
groups at 18% and 2%. Could this be a reflection again of 
sample size or, as mentioned, related to rewarming and 
overheating of the brain as in the documented findings 
that we found in our series? 
Third, the Mathews scale was used, which, as described 
in Lancet in 1972, used glycerol as a prospective protective 
agent for patients with stroke. In this study the modified 
version was used with nimodipine, which may not be the 
best method of determining and yet comparing the pres- 
ence or extent of neurologic events more subtle than a 
stroke. I would like to ask why more universal or perhaps 
comparable scales, such as the National Institutes of 
Health or Barthel scales, were not used in this series. 
Could there have been more subtle findings of neurologic 
dysfunction ot found because of the method of evalua- 
tion or sample size? 
Finally, I found that the fibrinolytic study, although 
interesting, appears to have begun late in the series and 
has groups perhaps too small to evaluate. Having one 
group size of six patients for five variables might stretch 
statistical power. 
I believe the authors have opened the discussion for a 
strategic compromise of perfusion temperature but I 
believe that more information is needed to finalize a 
recommendation. 
Dr. Engelman. I was also concerned and broached the 
subject of group distribution with our eminent statistician, 
who indicated that the distribution of groups was set up in 
such a fashion that on the basis of a series of 300, which 
was proposed, they would be essentially nearly equal. We 
are presenting our data on 130 patients, which clearly is 
less than even half of the proposed group, and that is why 
the groups are potentially unequal; but they are indeed 
random and our statistician said this was a valid presen- 
tation. 
With regard to the distribution of the neurologic dys- 
function, I can only say that this is what appeared. 
Whether it is a result of the different sample sizes between 
the warm and tepid groups that skewed the results, I
cannot speak to, but as I mentioned, we believed the 
sample size was adequate. 
With regard to the Mathews scale, this is our neurolo- 
gist's determination of an approach that he and his 
associates could perform reasonably expeditiously and, 
with the modification as described in the manuscript, he 
believed that this is an approach to evaluating neurologic 
function that is both reliable and reproducible. The 
conclusions that we have reached in this study are based 
on details of neurologic function that we believe are 
appropriate. 
With regard to the power of the fibrinolytic study, I 
would agree that clearly the number of patients at only 25 
is small, but it was interesting and quite statistically 
significant hat the difference between cold, tepid, and 
warm was so great in regard to at least plasminogen and 
prekallikrein. 
